Research
Hormonal
GLP-1 receptor agonists reduce cardiovascular risk in patients with obesity and established cardiovascular disease, even in the absence of diabetes.
For individuals with obesity and existing heart disease, GLP-1 medications like semaglutide can significantly reduce the risk of major cardiovascular events and promote weight loss, even without diabetes. This makes them a valuable tool for comprehensive heart health management.
StrongSupportsHIGH confidence
The results showed that semaglutide participants had an average weight loss of 10.2% over a four-year period, while the placebo group had an average weight loss of 1.5%. Semaglutide was found to have significant results in this study, not only for lowering weight but also for reducing adverse cardiovascular events.
Why this rating
Based on the large SELECT trial (17,604 participants).
Source
Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review
Alan D. Kaye et al. · Cureus · 2024
DOI 10.7759/cureus.76101
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) including semaglutide, tirzepatide, and liraglutide produce significant weight loss in adults with obesity, with efficacy increasing with higher doses and outperforming placebo.Strong
- GLP-1 receptor agonists reduce the formation of atherosclerotic plaques and lower inflammatory markers in patients with type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →